Updated Phase 2 Trial Data Looks Promising for Experimental Alpha-1 Antitrypsin Deficiency Therapy
source: shutterstock.com

Updated Phase 2 Trial Data Looks Promising for Experimental Alpha-1 Antitrypsin Deficiency Therapy

According to an a press release published on Business Wire, Arrowhead Pharmaceuticals Inc. recently presented updated phase 2 data at the 2023 European Association for the Study of the Liver…

Continue Reading Updated Phase 2 Trial Data Looks Promising for Experimental Alpha-1 Antitrypsin Deficiency Therapy
Certain Antibiotics Associated with Higher GvHD Risk Following Allo-HCT
[Source: pixabay.com]

Certain Antibiotics Associated with Higher GvHD Risk Following Allo-HCT

  Following allogeneic hematopoietic stem cell transplant (allo-HCT), which uses healthy stem cells from a donor, many doctors prescribe antibiotics to patients as a protective measure. Many individuals become neutropenic…

Continue Reading Certain Antibiotics Associated with Higher GvHD Risk Following Allo-HCT
Pembrolizumab Combo Fails to Reach Endpoint in Gastroesophageal Junction Cancer Trial
source: shutterstock.com

Pembrolizumab Combo Fails to Reach Endpoint in Gastroesophageal Junction Cancer Trial

According to a story from Healio, a phase 3 clinical trial evaluating pembrolizumab plus perioperative chemotherapy as a treatment for locally advanced and resectable gastric adenocarcinoma and gastroesophageal junction cancer…

Continue Reading Pembrolizumab Combo Fails to Reach Endpoint in Gastroesophageal Junction Cancer Trial
ICYMI: Enrollment Began in June for Hypoparathyroidism Natural History Study
mohamed_hassan / Pixabay

ICYMI: Enrollment Began in June for Hypoparathyroidism Natural History Study

How does hypoparathyroidism evolve and progress over time? Are available treatment and management strategies providing efficacious disease control? What are the long-term effects of hypoparathyroidism on overall health—and are there…

Continue Reading ICYMI: Enrollment Began in June for Hypoparathyroidism Natural History Study
Rare Community Profiles: Empathy through Art: A Mission to Raise Hypoparathyroidism Awareness
source: pixabay.com

Rare Community Profiles: Empathy through Art: A Mission to Raise Hypoparathyroidism Awareness

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Empathy through Art: A Mission to Raise Hypoparathyroidism Awareness
Study of the Week: Investigational Treatment Shows Promise for Treating Nonalcoholic Steatohepatitis
source: pixabay.com

Study of the Week: Investigational Treatment Shows Promise for Treating Nonalcoholic Steatohepatitis

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Investigational Treatment Shows Promise for Treating Nonalcoholic Steatohepatitis
Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares
source: shutterstock.com

Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares

  The World Health Organization (WHO) reports that an estimated 3.23 million people worldwide die each year from chronic obstructive pulmonary disease (COPD), making it the third leading cause of…

Continue Reading Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares